共 164 条
[1]
Herbst RS(2018)The biology and management of non-small cell lung cancer Nature 553 446-54
[2]
Morgensztern D(2014)Non-small-cell lung cancers: a heterogeneous set of diseases Nat Rev Cancer 14 535-46
[3]
Boshoff C(2021)Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observ ational study Lancet Public Health 6 e877-e87
[4]
Chen Z(2019)Systemic therapy for locally Advanced and Metastatic Non-small Cell Lung Cancer: a review JAMA 322 764-74
[5]
Fillmore CM(2019)Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet 393 1819-30
[6]
Hammerman PS(2021)Efficacy and safety of First-Line Immunotherapy combinations for Advanced NSCLC: a systematic review and network Meta-analysis J Thorac Oncol 16 1099-117
[7]
Kim CF(2018)Pembrolizumab plus Chemotherapy for squamous non-small-cell Lung Cancer N Engl J Med 379 2040-51
[8]
Wong KK(2020)Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Advanced squamous NSCLC (IMpower131): results from a Randomized Phase III Trial J Thorac Oncol 15 1351-60
[9]
Zeng H(2021)Tislelizumab Plus Chemotherapy vs Chemotherapy alone as first-line treatment for Advanced squamous non-small-cell Lung Cancer: a phase 3 Randomized Clinical Trial JAMA Oncol 7 709-17
[10]
Ran X(2021)Sintilimab Plus Platinum and Gemcitabine as First-Line treatment for Advanced or metastatic squamous NSCLC: results from a Randomized, Double-Blind, phase 3 trial (ORIENT-12) J Thorac Oncol 16 1501-11